The study collected clinical reports of nivolumab-induced cytokine release syndrome published before March 31, 2026, extracting clinical data for retrospective analysis. Thirty-five patients were included, spanning an extraordinarily wide age range from 3 to 86 years, with a median age of 55. That breadth alone carries a message for oncologists: the complication is not confined to any single tumor type, age group or treatment setting. It can emerge in children with refractory Hodgkin lymphoma and in elderly patients with solid tumors alike, wherever nivolumab is deployed to release the brakes on T-cell immunity.

Perhaps the most clinically consequential finding concerns timing. The median time from the start of nivolumab to the appearance of cytokine release syndrome was 54.5 days, with cases reported as early as 0.2 days and as late as 391 days after initiation. The median number of infusion cycles before onset was three, but the range stretched from one to seventeen. This late and highly variable onset distinguishes checkpoint inhibitor-associated cytokine release syndrome from the fulminant, early-onset syndrome seen after CAR T-cell infusion, where fever and hypotension typically erupt within days of cell transfer. A patient who develops fever and falling blood pressure months into nivolumab therapy may not immediately suggest a cytokine storm to the treating team, and the authors argue that the possibility of CRS should be explicitly considered throughout the entire course of administration, not just in the first weeks.

The clinical signature the researchers documented is dominated by fever, which affected 85.7 percent of patients. Hypotension followed in 57.1 percent, tachycardia in 42.9 percent, and fatigue, rash and impaired consciousness each appeared in 25.7 percent of cases. This constellation mirrors the physiology of uncontrolled immune activation: activated T cells and macrophages flood the circulation with inflammatory mediators, producing capillary leak, vasodilation and hemodynamic instability. Neurological involvement in the form of impaired consciousness underscores that the brain is not spared when cytokine levels climb, a feature also recognized in severe CAR T-cell-associated toxicity. In practical terms, a patient on nivolumab who presents with unexplained fever plus hypotension or altered mental status should raise immediate suspicion of CRS, even if the last infusion was months earlier.

Laboratory findings reinforce the inflammatory diagnosis. The reviewed cases commonly revealed liver injury, renal injury, elevated C-reactive protein, elevated ferritin and elevated interleukin-6. Each of these markers has a mechanistic rationale. Interleukin-6 is a central driver of the syndrome, amplifying the inflammatory cascade and contributing to vascular permeability. Ferritin, an acute-phase reactant produced abundantly by activated macrophages, has been proposed in prior literature as a diagnostic and prognostic marker for immune-related adverse events. C-reactive protein rises rapidly under interleukin-6 stimulation and serves as a readily available readout of systemic inflammation. Hepatic and renal abnormalities reflect both direct inflammatory organ injury and the hemodynamic consequences of vasodilatory shock, in which reduced perfusion compounds cytokine-mediated tissue damage.

Treatment in the collected cases followed two main pillars: discontinuation of nivolumab and immunosuppressive or immunomodulatory therapy directed at the cytokine cascade itself. Glucocorticoids and tocilizumab, a monoclonal antibody that blocks the interleukin-6 receptor, were widely utilized as the primary therapeutic approaches. After these interventions, 71.4 percent of patients showed improvement in symptoms and clinical markers. The remaining 28.6 percent died. That mortality figure, drawn from published case reports that may overrepresent severe presentations, nevertheless signals that nivolumab-induced cytokine release syndrome can lead to multi-organ functional impairment and can be fatal. The authors emphasize that the syndrome is not a benign infusion reaction but a potentially life-threatening emergency requiring prompt recognition.

The choice of tocilizumab as first-line therapy reflects experience imported from the CAR T-cell field, where interleukin-6 receptor blockade has become standard for severe cytokine release syndrome and is embedded in consensus grading systems such as the ASTCT criteria and in clinical practice guidelines from the Society for Immunotherapy of Cancer and the American Society of Clinical Oncology. Glucocorticoids, which broadly suppress T-cell and macrophage activation, are typically layered on when tocilizumab alone is insufficient or when neurological symptoms are present. For refractory cases, the broader literature on immune effector cell toxicities describes additional salvage options, including plasma exchange, but the evidence base for such measures in checkpoint inhibitor-associated CRS remains thin and largely anecdotal.

Herein lies the central limitation the authors acknowledge: the standardized and optimal treatment strategy for nivolumab-induced cytokine release syndrome remains undefined. Because the analysis is retrospective and built from individually published case reports, it is vulnerable to reporting bias, inconsistent grading and inherent clinical confounders. Patients described in case reports are often the sickest, which may inflate the apparent mortality, and concomitant medications, infections, combination immunotherapy regimens and underlying malignancies can all mimic or exacerbate the syndrome. The researchers also note that the available evidence base is limited, meaning that while glucocorticoids and tocilizumab are the de facto standards in clinical practice, no prospective trial has defined the ideal timing, dosing or sequencing of these agents specifically for nivolumab-triggered CRS.

The mechanistic puzzle is also unresolved. Nivolumab blocks programmed death-1, a checkpoint receptor that restrains T-cell activity, and cytokine release syndrome after checkpoint blockade is thought to arise when reinvigorated T cells expand and secrete interferon and other mediators that activate macrophages and endothelial cells. Why only a small fraction of the many thousands of patients treated with nivolumab develop this syndrome is unknown, though prior pharmacovigilance analyses of WHO data and case series of checkpoint inhibitor-associated CRS suggest the event is rare and may be more frequent with combination regimens such as ipilimumab plus nivolumab. Host genetic factors influencing interleukin-6 biology, tumor burden, and individual immune repertoire dynamics are plausible contributors that current data cannot disentangle.

For clinicians, the practical takeaways are concrete. Fever developing during nivolumab therapy, particularly when accompanied by hypotension, tachycardia, rash or confusion, should prompt evaluation for cytokine release syndrome rather than automatic attribution to infection or tumor progression. Measurement of C-reactive protein, ferritin and interleukin-6 can support the diagnosis, and early involvement of intensive care may be warranted given the risk of hemodynamic collapse and multi-organ failure. For researchers, the study defines the agenda: prospective registries, standardized grading using consensus CRS criteria, and controlled evaluation of tocilizumab and corticosteroid protocols are needed to move management from case-report empiricism to evidence-based practice. Until then, vigilance remains the most powerful tool, because the window in which glucocorticoids and interleukin-6 blockade can reverse the inflammatory cascade is likely narrow, and the price of missing it, in roughly one of the patients captured in this analysis, was fatal.

Subject of Research: Cytokine release syndrome induced by the immune checkpoint inhibitor nivolumab

Article Title: Clinical characteristics, treatment and prognosis of nivolumab induced cytokine release syndrome

Article References: Zhao, S., Sun, W., Peng, L., & Wang, C. (2026). Clinical characteristics, treatment and prognosis of nivolumab induced cytokine release syndrome. Supportive Care in Cancer, 34(10), Article 1039. https://doi.org/10.1007/s00520-026-11303-8

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11303-8

Keywords: nivolumab, cytokine release syndrome, immune checkpoint inhibitors, tocilizumab, glucocorticoids, interleukin-6, immune-related adverse events, ferritin, hypotension, immunotherapy toxicity, PD-1 inhibitor, retrospective analysis

The research, led by Grzegorz Fiutak of the University of Agriculture in Krakow together with Barbara Stefanska of the University of British Columbia and an international team spanning Poland and Canada, set out to answer a question that has long lingered at the margins of plant photobiology. Scientists know a great deal about how red, blue, and far-red light shape plant growth, because these wavelengths are absorbed by the pigments that drive photosynthesis and regulate development. But the near-infrared region beyond the far-red — roughly the band where 850 and 940 nanometer LEDs operate — has remained poorly understood. These wavelengths are widely used in consumer wellness devices and industrial heating applications, yet their direct effects on plant biochemistry, independent of photosynthesis, had not been systematically explored in an edible crop.

To probe the question, the team grew radish sprouts in complete darkness and compared them with sprouts cultivated under monochromatic near-infrared LEDs at 850 nanometers and 940 nanometers, with no visible light supplied at all. This design was critical: by excluding photosynthetically active radiation, the researchers could isolate any metabolic effects of near-infrared light from the familiar machinery of photosynthesis. They then subjected the harvested sprouts to an extensive battery of analyses, measuring dry matter, fiber, protein content, amino acid profiles, ascorbic acid, chlorophylls, carotenoids, anthocyanins, and phenolic compounds using high-performance liquid chromatography and other analytical techniques. Finally, they tested whether extracts from the sprouts had measurable biological activity in cell-based assays.

The results were striking in their wavelength specificity. Sprouts grown under 940 nanometer radiation accumulated the highest protein content of any treatment, while maintaining a stable amino acid profile and high protein quality — meaning the extra protein was not simply diluted in quality but retained a balanced composition of essential amino acids. This is a notable outcome for a crop grown entirely without visible light, and it suggests that deep near-infrared exposure may influence nitrogen metabolism or protein synthesis pathways through mechanisms that do not depend on photosynthetic energy capture. For controlled-environment agriculture, where protein enrichment of crops is an ongoing goal, the finding points to a potentially simple lever: changing the wavelength of supplementary lighting rather than altering inputs like fertilizer.

The 850 nanometer treatment told a very different story. Rather than boosting protein, this wavelength promoted the accumulation of ascorbic acid — vitamin C — along with anthocyanins, the pigments responsible for red and purple coloration in plants, and several carotenoids. The effect was visible to the naked eye: sprouts under 850 nanometer light developed more intense red pigmentation than their dark-grown counterparts. Anthocyanins are of intense interest to food scientists because of their antioxidant and anti-inflammatory properties, and carotenoids such as lutein are valued for their roles in eye health and as dietary antioxidants. The fact that a single, precisely chosen invisible wavelength could elevate these compounds without any photosynthetic input is the kind of result that lends itself to immediate application in vertical farming and sprout production facilities.

Importantly, the two treatments shared some common ground. Both 850 and 940 nanometer radiation increased the concentrations of lutein, violaxanthin, and selected derivatives of sinapic acid relative to sprouts grown in darkness. Sinapic acid derivatives belong to the broad family of phenolic compounds that plants deploy as chemical defenses and antioxidants. Their elevation under both wavelengths indicates that near-infrared exposure, even beyond the far-red region, acts as an elicitor of secondary metabolism — the branch of plant biochemistry responsible for producing many of the compounds humans prize in fruits, vegetables, and herbs. At the same time, some fundamentals proved stubbornly resistant to manipulation: dry matter, fiber content, and the overall amino acid composition of the sprouts remained unaffected by either treatment, and neither wavelength restored chlorophyll synthesis or prevented the etiolated growth pattern typical of plants raised in the dark.

Perhaps the most intriguing results came from the biological activity assays. The team extracted carotenoids from the sprouts using acetone-based methods and tested these extracts on Raw 264.7 macrophages, a widely used mouse cell line in immunology research. The cells were stimulated with lipopolysaccharide, a bacterial molecule that triggers a strong inflammatory response, and the researchers measured the production of interleukin-6, a pro-inflammatory signaling molecule implicated in chronic inflammatory diseases. The extracts from sprouts grown under 940 nanometer radiation were the most effective at reducing lipopolysaccharide-induced interleukin-6 production, outperforming extracts from the dark-grown and 850 nanometer treatments. While cell-culture findings are an early step and cannot be directly translated into health claims for consumers, they provide a proof of concept that light-grown sprouts can carry not just different nutrient profiles but measurably different bioactivity.

The broader significance of the study lies in what it says about light as a tool rather than merely as fuel. Photosynthesis is the process by which plants convert visible light into chemical energy, and most agricultural lighting strategies are built around maximizing it. But plants are also exquisitely sensitive photoreceivers in other ways, and this work demonstrates that near-infrared radiation beyond the far-red range modifies plant metabolism independently of photosynthesis altogether. In practical terms, this means growers could potentially use narrow-band near-infrared LEDs as elicitors — a kind of biochemical seasoning applied through the lighting system — to tailor crops for specific nutritional or functional goals. A producer targeting protein enrichment might favor 940 nanometer supplementation, while one aiming to maximize antioxidant content and visual appeal might choose 850 nanometers.

The implications extend to sustainability as well. Sprouts are among the most resource-efficient foods humans produce, requiring minimal water, space, and time from seed to harvest, and they are increasingly grown in controlled-environment facilities where every aspect of light, temperature, and humidity can be tuned. If a simple change in LED wavelength can elevate vitamin C, anthocyanins, carotenoids, or protein in such a crop without additional agricultural inputs, the energy cost of that intervention may be modest compared with the nutritional gain. The authors suggest that wavelength-specific near-infrared radiation could become a practical instrument in controlled-environment agriculture and sustainable functional food production, complementing the red and blue lighting that dominates indoor farms today.

There remain open questions, as with any early-stage finding. The study was conducted on a single crop species, radish, and the mechanisms by which 850 and 940 nanometer light exert their distinct effects on protein accumulation and secondary metabolism have not yet been fully mapped. Whether the same wavelength-specific responses hold for other sprouts, leafy greens, or fruiting crops is unknown, and the anti-inflammatory signal observed in macrophage cultures will need to be followed through further biological testing before any dietary relevance can be established. Still, the central message is clear and, for a field accustomed to thinking about light in terms of photosynthetically active radiation, genuinely surprising: there is useful information in the invisible part of the spectrum, and plants are listening. As indoor farming scales up around the world, the humble radish sprout — grown in the dark, bathed in light no one can see — may turn out to be an early glimpse of a new kind of precision agriculture, one where the recipe for a more nutritious vegetable is written in nanometers.

Subject of Research: Effects of near-infrared LED radiation on the biochemistry and biological activity of radish sprouts

Article Title: Biochemical composition and biological activity of radish sprouts grown in near-infrared radiation

Article References: Fiutak, G., Filipczak-Fiutak, M., Sady, M., Jarzębski, M., Mohammadi, X., Klein, G.-R., Relova-Clegg, E., Pratap-Singh, A., Świąder, K., Kapusta, I., Kołton, A., Tabaka, P., Grabacka, M., & Stefanska, B. (2026). Biochemical composition and biological activity of radish sprouts grown in near-infrared radiation. BMC Plant Biology. https://doi.org/10.1186/s12870-026-10053-3

Image Credits: AI Generated

DOI: 10.1186/s12870-026-10053-3

Keywords: near-infrared radiation, radish sprouts, carotenoids, anthocyanins, ascorbic acid, protein content, plant biochemistry, LED lighting, controlled-environment agriculture, functional foods, interleukin-6, photobiology

The therapeutic platform, designated E-sEVs@CHA, combines two innovations that address the two biggest bottlenecks in regenerative medicine for the esophagus. The first is the extracellular vesicles themselves. Small extracellular vesicles, often called exosomes, are nanoscale membrane-bound packets released by cells that carry microRNAs, proteins, and lipids. Mesenchymal stem cells, particularly those derived from umbilical cord tissue, are prized for the immunomodulatory and pro-regenerative cargo of their vesicles, but naive vesicles from unstimulated cells often lack the potency needed to meaningfully alter a hostile injury environment. The research team, led by Dan Luo and Baoxiang Wang, tackled this by preconditioning the umbilical cord-derived mesenchymal stem cells with interleukin-6, a master regulator of the acute inflammatory response, for 24 hours before collecting the vesicles.

The logic behind this cytokine priming rests on a growing understanding that the therapeutic function of mesenchymal stem cells is not fixed but dynamically licensed by their surroundings. When exposed to inflammatory signals, the cells upregulate key immunomodulatory factors such as COX-2 and TSG-6, and their vesicles inherit an amplified capacity to calm immune overreactions and promote repair. Previous work has shown that preconditioning with interferon-gamma, tumor necrosis factor-alpha, or interleukin-1 beta can supercharge vesicles for treating endometritis, colitis, and other inflammatory conditions. In the new study, interleukin-6 stimulation increased both the particle concentration and protein content of the harvested vesicles, with E-sEVs reaching 1.25 x 10^11 particles per milliliter and 1.40 milligrams of protein per milliliter, compared with 0.91 x 10^11 particles and 1.08 milligrams for naive vesicles. Transmission electron microscopy confirmed that both populations displayed the characteristic circular, double-layered membrane morphology, with average diameters around 70 nanometers.

In laboratory assays, the enhanced vesicles proved decisively more capable than their naive counterparts. When lipopolysaccharide-stimulated macrophages were treated with E-sEVs, expression of the pro-inflammatory cytokines TNF-alpha and iNOS fell sharply while the anti-inflammatory mediators IL-10 and Arg-1 rose. Flow cytometry revealed that the primed vesicles drove macrophages from the aggressive M1 phenotype toward the reparative M2 phenotype far more effectively than naive vesicles, whether starting from resting M0 macrophages or from LPS-polarized M1 cells. The vesicles also demonstrated antioxidant power: in endothelial and esophageal epithelial cells stressed with hydrogen peroxide, E-sEVs reduced reactive oxygen species accumulation and preserved mitochondrial membrane potential better than naive vesicles or the carrier alone. In a fibrosis model induced by transforming growth factor-beta, the primed vesicles more strongly suppressed the fibrotic markers alpha-SMA and type I collagen in fibroblasts.

The second innovation is the delivery vehicle. The esophagus is a hostile environment for any locally administered therapy because its muscular walls generate continuous peristaltic waves that sweep away conventional formulations within minutes. To overcome this, the researchers turned to cationic hyaluronic acid, a derivative of the natural extracellular matrix molecule modified with positively charged groups. These positive charges promote electrostatic adhesion to the negatively charged cell surfaces and matrix components of injured tissue, prolonging residence time. The team systematically tested concentrations from 5 to 20 percent by weight, measuring how far the viscous fluid slid down vertical surfaces of paper, plastic, latex, and porcine skin. At 5 percent, the gel flowed away too quickly to retain a therapeutic payload; at 20 percent, it was nearly immobile and risked obstructing the esophagus. The sweet spot, 15 percent, balanced strong adhesion with smooth injectability through a gavage needle, and release experiments showed that more than 70 percent of loaded vesicles were liberated within six hours.

Safety testing of the carrier was thorough. Live-dead staining and proliferation assays in fibroblasts showed no cytotoxicity, and hemolysis rates remained below 2 percent, well within biomaterial safety thresholds. When 15 percent CHA was instilled into healthy rats daily for 28 days, blood chemistry markers of liver and kidney function, including ALT, AST, creatinine, uric acid, and urea nitrogen, showed no significant differences from controls, and histological examination of the esophagus, heart, liver, spleen, lung, and kidneys revealed no pathological changes. The authors attribute this biocompatibility partly to the modest degree of cationization, only 23 percent, and to the gel-like polymeric structure, which avoids the membrane-disrupting behavior seen with highly charged nanoparticle carriers such as PEI.

The decisive test came in a rat model of corrosive esophageal injury. The researchers induced injury by instilling 15 percent sodium hydroxide solution into the esophagus, a protocol that produced clear mucosal damage and, by day 28, significant fibrotic narrowing confirmed by esophagography and Masson staining. Rats then received intraesophageal instillations of either the carrier alone, naive vesicles in the carrier, or the enhanced E-sEVs@CHA formulation every other day. Early on, at day 8, histology showed that treated animals retained intact mucosal and muscularis layers while untreated injured rats suffered structural disruption and heavy inflammatory infiltration. Molecular analysis confirmed that the combination therapy significantly reduced messenger RNA levels of the pro-inflammatory cytokines IL-1beta, IL-6, and TNF-alpha while boosting anti-inflammatory IL-10, with the primed formulation showing a particularly strong inhibitory effect on IL-6.

By day 28, the differences were striking. Esophagography revealed severe luminal narrowing in untreated injured rats, only limited improvement with the carrier alone, and modest benefit with naive vesicles, but the E-sEVs@CHA group maintained a significantly widened esophageal passage approaching that of healthy controls. Masson staining and quantitative collagen analysis showed that the primed formulation produced the greatest reduction in collagen deposition, and expression of the fibrotic genes TGF-beta, alpha-SMA, and collagen I was most strongly suppressed in this group. Fluorescent tracking in mice demonstrated that the adhesive carrier extended vesicle retention in the esophagus to roughly two to three hours, compared with rapid clearance for free vesicles. While the authors acknowledge this retention window is short, they argue that vesicles are rapidly internalized by target cells and can trigger sustained downstream signaling even after the extracellular payload has cleared.

To understand why the primed vesicles outperformed naive ones, the team performed small RNA sequencing and label-free quantitative proteomics. They identified 168 differentially expressed microRNAs between the two vesicle populations, with three standing out: miR-1246, miR-193a-5p, and miR-1290. The predicted targets of these microRNAs were enriched in signaling pathways central to cell proliferation, migration, and tissue repair, including PI3K-Akt, MAPK, cAMP, and HIF-1. Notably, miR-1246 was downregulated in the primed vesicles; because this microRNA normally suppresses PIK3AP1 and thereby restrains PI3K-Akt signaling, its reduction could theoretically unleash pro-survival and pro-migratory programs in esophageal epithelial cells. Proteomic analysis showed that the primed vesicles carried increased amounts of extracellular matrix components such as COL1A2, COL5A1, and VCAN, which may provide a provisional scaffold for cell anchorage, while inflammatory chemokines like IL-6, CCL2, and CXCL1, along with complement proteins and coagulation factors, were reduced, suggesting a shift toward a regenerative, low-inflammation microenvironment. Differentially expressed proteins were significantly enriched in the JAK-STAT pathway, a signaling hub that crosstalks extensively with PI3K-Akt, MAPK, and HIF-1.

The study positions E-sEVs@CHA as a multi-phasic therapy matched to the three overlapping phases of corrosive injury: acute necrosis, inflammatory response, and chronic fibrosis. By acutely damping cytokine storms and oxidative damage while chronically inhibiting the fibrotic remodeling that produces strictures, the system addresses the full pathological arc rather than merely dilating the aftermath. The findings also build on earlier work showing that adipose-derived stem cell exosomes in chitosan sponges prevented strictures in a porcine model, and they contrast with a prior report that a single intravenous dose of mesenchymal stem cells failed to heal caustic esophageal injury in rats, underscoring the importance of both vesicle priming and repeated local delivery through a bioadhesive scaffold. The authors caution that retention time remains a limitation and that repeated dosing or chemical modification of the hydrogel could further improve outcomes, but the strategy offers a compelling, cell-free blueprint for a condition that currently has few good options.

Subject of Research: A bioadhesive hydrogel delivering IL-6-primed mesenchymal stem cell extracellular vesicles for repairing corrosive esophageal injury

Article Title: Adhesive cationic hyaluronic acid loading with small extracellular vesicles from IL-6 activated mesenchymal stem cells improves repair of corrosive esophageal injury

Article References: Adhesive cationic hyaluronic acid loading with small extracellular vesicles from IL-6 activated mesenchymal stem cells improves repair of corrosive esophageal injury. (n.d.). https://doi.org/10.1016/j.mtbio.2026.103706

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103706

Keywords: corrosive esophageal injury, extracellular vesicles, exosomes, mesenchymal stem cells, interleukin-6, cationic hyaluronic acid, bioadhesive hydrogel, esophageal stricture, anti-fibrosis, macrophage polarization, drug delivery, regenerative medicine

The biology of CRS begins the moment engineered T cells recognize their target. CAR T cells are autologous lymphocytes genetically modified to express synthetic receptors that bind tumor-associated antigens such as CD19 or BCMA. Upon antigen engagement, the cells unleash perforin and granzyme to kill malignant cells while simultaneously secreting a cocktail of pro-inflammatory signaling proteins, including interferon-gamma, tumor necrosis factor alpha, GM-CSF, and interleukin-2. These signals then recruit and activate innate immune players, chiefly monocytes and macrophages, which respond by pouring out interleukin-6 and interleukin-1 beta. This amplification loop between adaptive and innate immunity is what transforms a targeted attack into a systemic cytokine storm. Vascular endothelial cells become activated, blood vessels leak, and patients develop the classic clinical picture: fever, fatigue, hypotension, hypoxia, and in the worst cases multi-organ dysfunction. In severe instances, the syndrome can escalate into an immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome and contribute to disruption of the blood-brain barrier, setting the stage for neurological complications.

How sick a patient becomes is not a matter of chance. Tumor burden at baseline, the specific CAR construct used, and the magnitude of T-cell expansion all shape the intensity of the inflammatory response. The intracellular costimulatory domain built into the receptor plays a particularly important role: constructs carrying the CD28 domain drive rapid T-cell expansion and are associated with a higher incidence of acute, severe adverse events, whereas 4-1BB-based constructs expand more slowly and persistently, producing a more gradual and generally less toxic immune response. Higher CAR T-cell doses enhance antitumor efficacy but also raise the risk of massive simultaneous T-cell activation. Patient factors matter as well. Elevated pre-infusion inflammatory markers such as interleukin-6 and C-reactive protein, advanced age, cardiovascular or renal comorbidities, certain lymphoma subtypes including primary mediastinal B-cell lymphoma, and pediatric or young adult patients treated for acute lymphoblastic leukemia all signal elevated risk. Bridging therapy to shrink the tumor before infusion is one practical strategy to lower the odds of explosive cytokine release.

Accurate grading is the backbone of treatment decisions. The consensus system from the American Society for Transplantation and Cellular Therapy classifies CRS into four grades based on fever, hypotension, hypoxia, and organ toxicity, deliberately moving beyond fever alone to incorporate the need for vasopressors and supplemental oxygen. Grade 1 disease, essentially fever by itself, is usually managed conservatively with antipyretics and observation. Grade 2, marked by hypotension or mild hypoxia, requires hospital monitoring and often pharmacologic intervention. Grade 3 and 4 cases, involving refractory low blood pressure, multisystem injury, shock, or respiratory failure, demand escalation to corticosteroids, vasopressors, and intensive care, with mechanical ventilation reserved for the critically ill. Because the boundary between CRS and sepsis can be blurred, clinicians must constantly weigh early immunosuppression against the danger of masking an underlying infection, a balancing act that defines much of the day-to-day management of these patients.

At the center of the pharmacologic arsenal sits tocilizumab, a monoclonal antibody that blocks the interleukin-6 receptor and remains the only drug approved by the FDA specifically for CRS. By interrupting the interleukin-6 signaling axis, it rapidly reverses fever, hypotension, and capillary leak without impairing the antitumor activity of the CAR T cells, and in most patients one or two doses suffice to control grade 2 or higher disease. Its speed has made it the emergency drug of choice, stocked in treatment centers with STAT ordering protocols. But tocilizumab is not without caveats. Blocking the receptor can cause circulating interleukin-6 levels to rebound, and there is concern that unbound cytokine may then cross the blood-brain barrier, potentially triggering or worsening immune effector cell-associated neurotoxicity syndrome, known as ICANS. This interplay between the two syndromes complicates therapy, since ICANS typically emerges days after CRS onset and, unlike CRS, does not respond to tocilizumab because the antibody penetrates the central nervous system poorly.

For patients who fail interleukin-6 blockade or who develop neurological symptoms, corticosteroids such as dexamethasone and methylprednisolone serve as the crucial second line. Historical worries that steroids might blunt CAR T-cell proliferation have been tempered by more recent evidence showing that early administration at moderate doses and limited duration does not significantly compromise antitumor efficacy. Typical regimens involve intravenous dexamethasone at 10 milligrams every six hours or methylprednisolone at 1 to 2 milligrams per kilogram per day, tapered over three to five days according to clinical response. Beyond steroids, a growing set of targeted agents is expanding the toolkit. Anakinra, an interleukin-1 receptor antagonist, crosses the blood-brain barrier readily and is increasingly valued for tocilizumab-refractory CRS and concurrent neurotoxicity. Lenzilumab, targeting GM-CSF, and emapalumab, targeting interferon-gamma, are under clinical evaluation for severe or steroid-refractory disease. In a striking example of drug repurposing, the beta-blocker metoprolol has been shown in laboratory and clinical studies to directly inhibit interleukin-6 translation in human monocytes, reducing CRS severity without harming CAR T-cell function and opening a novel therapeutic target: the protein synthesis machinery of inflammatory cells.

Monitoring is where modern CRS care increasingly meets data science. Routine protocols call for daily ferritin, C-reactive protein, and cytokine panels during the first ten days after infusion, or longer in high-risk patients, because rising interleukin-6, ferritin, and CRP levels precede clinical symptoms and correlate with severity. Soluble interleukin-2 receptor and coagulation markers flag the hemophagocytic syndrome variant and coagulopathy. Artificial intelligence is now pushing surveillance further. A model called PrCRS, built on U-Net and Transformer architectures with transfer learning, can predict severe CRS one to three days before symptom onset. Other multimodal machine learning systems analyze vital signs, laboratory results, and early cytokine profiles to identify high-risk patients within hours of infusion, and an explainable algorithm proposed by Bogatu and colleagues incorporates domain literature to detect CRS from cytokine peak levels despite limited training data. Real-time dashboards linked to electronic health records are already being piloted at academic centers, alerting care teams and enabling preemptive tocilizumab or steroid administration based on algorithmic triggers.

None of these tools work in isolation, and the review emphasizes that the hallmark of contemporary CRS management is multidisciplinary coordination. Optimal outcomes emerge when hematologists, oncologists, intensivists, neurologists, infectious disease specialists, pharmacists, and specialized nurses operate under unified protocols with rapid triage pathways and seamless escalation from ward to intensive care. Many centers have established cellular therapy toxicity boards, early warning systems, and dedicated CAR T-cell response teams equipped with predesigned protocols, immediate drug access, and intensive care beds on standby. Standardized operating procedures embed CRS and ICANS flowcharts directly into electronic medical records, while simulation training for nurses and residents sharpens recognition of early warning signs. Age also shapes strategy: pediatric patients generally tolerate higher cytokine loads, so clinicians lean on supportive care and reserve steroids for refractory cases, whereas elderly patients, vulnerable to cardiovascular and renal decompensation, warrant a lower threshold for early intervention, cardiac monitoring, and bridging therapy to reduce disease burden before infusion.

Looking ahead, the field is moving from reactive treatment to engineered prevention. Ruxolitinib, a Janus kinase 1/2 inhibitor, dampens downstream signaling from multiple cytokines and may help when interleukin-6 blockade alone is insufficient. Siltuximab, which binds interleukin-6 directly rather than its receptor, offers an alternative where receptor blockade falls short. More radically, next-generation CAR constructs are being designed with safety built in: bispecific and split-signaling receptors that require dual-antigen recognition to activate, ON/OFF-switch systems controlled by administered small molecules, suicide genes such as inducible caspase 9, and so-called armored CARs that co-express anti-cytokine payloads like interleukin-1 receptor antagonists to neutralize inflammation at its source. Researchers are also probing the upstream triggers of CRS, implicating inflammasome activation, pyroptotic cell death, and tissue-resident macrophages, and pursuing multi-omics biomarker discovery to shift management from reactive to proactive. Together, these advances promise to widen the therapeutic window of CAR T-cell therapy, allowing its remarkable curative potential to reach broader and more fragile patient populations safely.

Subject of Research: Management of cytokine release syndrome following CAR T-cell therapy

Article Title: Management of Cytokine Release Syndrome (CRS) following CAR T-cell therapy: a comprehensive review

Article References: Zhang, Y., & Han, W. (2025). Management of Cytokine Release Syndrome (CRS) following CAR T-cell therapy: a comprehensive review. Clinical Cancer Bulletin, 4(1), Article 15. https://doi.org/10.1007/s44272-025-00044-0

Image Credits: AI Generated

DOI: 10.1007/s44272-025-00044-0

Keywords: CAR T-cell therapy, cytokine release syndrome, tocilizumab, ICANS, immunotherapy toxicity, interleukin-6, corticosteroids, anakinra, biomarkers, artificial intelligence prediction, risk stratification, hematological malignancies

The core argument of the review is that inflammaging rewires the cytokine networks that coordinate both innate and adaptive immune responses. As the immune system ages, pro-inflammatory signals such as interleukin-6 and interleukin-1 rise while regulatory, anti-inflammatory mediators falter. This imbalance promotes endothelial dysfunction, compromises post-infarction repair and makes the aged myocardium more susceptible to ischemia and adverse remodeling. In practical terms, an older heart does not merely suffer a blocked artery; it responds to that insult with an immune reaction that has been fundamentally altered by decades of inflammatory conditioning.

A central player in this process is cellular senescence, the state in which aged or damaged cells stop dividing but refuse to die, instead secreting a potent cocktail of inflammatory molecules known as the senescence-associated secretory phenotype, or SASP. The review details how senescent cells in the cardiovascular system, including endothelial cells, vascular smooth muscle cells and cardiomyocytes, perpetuate inflammaging by continuously releasing cytokines, chemokines and matrix-remodeling enzymes. This creates a self-reinforcing loop: inflammation drives senescence, and senescent cells amplify inflammation, progressively degrading the structural and functional integrity of the heart and vasculature.

The authors also devote significant attention to inflammasome-mediated pyroptosis, a highly inflammatory form of programmed cell death. When danger signals such as mitochondrial DNA, HMGB1 or S100 alarmin proteins are released from damaged tissue, they can activate the NLRP3 inflammasome, triggering gasdermin D pore formation and explosive release of interleukin-1 beta and interleukin-18. Evidence compiled in the review indicates that this pathway is amplified in the aging heart, contributing to cardiac aging itself and worsening ischemia-reperfusion injury after a heart attack. Experimental studies cited suggest that suppressing NLRP3 can prevent cardiac aging and improve longevity in animal models, and pharmacological inhibitors such as dapansutrile have already been tested in early human trials for heart failure.

On the translational front, the review identifies the interleukin-6 and interleukin-1 signalling axis as the target with the strongest interventional evidence to date. The landmark CANTOS trial demonstrated that canakinumab, a monoclonal antibody against interleukin-1 beta, reduced recurrent cardiovascular events in patients with atherosclerotic disease, providing the first outcome-level proof that tamping down this inflammatory arm can benefit the heart. Meanwhile, the Norwegian ASSAIL-MI trial provided phase 2 myocardial-salvage evidence for tocilizumab, an interleukin-6 receptor blocker, in patients experiencing acute ST-elevation myocardial infarction, with additional analyses documenting favorable shifts in immune cell profiles after interleukin-6 inhibition.

Beyond interleukin-6 and interleukin-1, the review catalogues a dense web of cytokines and chemokines implicated in age-related cardiac injury. Chemokines such as CCL2 and CXCL12 orchestrate monocyte recruitment and stem cell homing, while members of the interleukin-17 family drive fibrosis and arrhythmogenesis after infarction. In contrast, anti-inflammatory interleukins including IL-37, IL-38 and IL-22 appear cardioprotective, attenuating platelet activation, macrophage inflammation and fibroblast metabolic reprogramming. Growth factors such as GDF11 and the longevity-associated protein Klotho add further layers of complexity, with circulating levels shifting in ways that can either exacerbate or mitigate myocardial injury depending on context.

Emerging biomarkers form another pillar of the review. The authors highlight cytokine-based and extracellular vesicle-based diagnostics as promising tools for stratifying cardiovascular risk in older patients. Multiplexed and point-of-care biosensing technologies, augmented by artificial intelligence and machine learning, are making it feasible to track inflammatory signatures in real time. Notably, a deep-learning-derived inflammatory aging clock based on cytokine profiles has been shown to track multimorbidity, immunosenescence, frailty and cardiovascular aging, offering a glimpse of how inflammaging measurements could one day guide personalized treatment decisions in elderly patients presenting with acute coronary syndromes.

The concept of trained immunity also features prominently. Innate immune cells can retain epigenetic and metabolic memories of prior insults, and this memory program appears to be dysregulated in aging and atherosclerosis, fueling exaggerated inflammatory responses. Clonal hematopoiesis, the age-related expansion of genetically altered blood cell clones such as those carrying TET2 mutations, has been shown to accelerate atherosclerosis through inflammatory mechanisms, linking hematopoietic aging directly to cardiovascular risk. Interventions ranging from lifestyle modification to exercise, which promotes anti-inflammatory cytokine release and counters cellular senescence, are discussed as accessible means of tempering inflammaging, alongside nutraceutical and pro-resolving lipid mediator strategies.

Senescence-directed therapeutics represent an especially forward-looking frontier. Senolytic drugs, which selectively eliminate senescent cells, have shown promise in preclinical cardiovascular models, and engineered senolytic CAR T cells have reversed senescence-associated pathologies in experimental systems. Engineered extracellular vesicles are being explored as targeted delivery platforms capable of ferrying microRNAs and other payloads to damaged myocardium. The review argues that combining cytokine-targeted agents with senescence-directed and precision immunology-guided approaches could eventually allow clinicians to tailor anti-inflammatory therapy to the immune fingerprint of each aging patient, a vision embodied by European initiatives aimed at personalized cardiovascular care.

Crucially, the authors temper their optimism with caution. Despite encouraging signals from CANTOS, ASSAIL-MI and related studies, the efficacy and safety of cytokine-based immunotherapies in older populations remain to be established in dedicated clinical trials, and elderly patients are chronically underrepresented in cardiovascular research. Sex and gender differences in immune aging, the influence of the gut microbiota, and the heterogeneity of inflammaging across individuals all complicate the path to precision treatment. Nevertheless, the review concludes that inflammaging is tightly linked to age-related myocardial infarction, and that immunotherapies targeting the interleukin-6 and interleukin-1 axis constitute one of the most promising therapeutic avenues for protecting the aging heart in the years ahead.

Subject of Research: The role of inflammaging and cytokine-driven cardiovascular senescence in age-related myocardial infarction and precision immunotherapy

Article Title: Inflammaging and cytokine-driven cardiovascular senescence in age-related myocardial infarction: mechanisms, biomarkers, and precision immunotherapy strategies

Article References: Aung, S., Phyu, S. E., Giribabu, N., & Salleh, N. (2026). Inflammaging and cytokine-driven cardiovascular senescence in age-related myocardial infarction: mechanisms, biomarkers, and precision immunotherapy strategies. Biogerontology, 27(5), Article 152. https://doi.org/10.1007/s10522-026-10482-5

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10482-5

Keywords: inflammaging, myocardial infarction, cytokines, cardiovascular senescence, NLRP3 inflammasome, pyroptosis, senescence-associated secretory phenotype, interleukin-6, interleukin-1, precision immunotherapy, biomarkers, aging

The research team set out to address a persistent gap in reproductive virology. Viral infections in the female reproductive tract are well known to pose risks to fertility, and previous studies in mice have shown that viral infection of the ovaries can compromise pregnancy. Yet the specific impact of viruses on ovulated oocytes—the mature eggs that have just been released from the ovary—and the role played by the surrounding cumulus cells remained poorly understood. Cumulus cells form a layered, cloud-like structure called the cumulus oophorus around the oocyte, and together the egg and its companion cells are known as the cumulus–oocyte complex, or COC. This intimate relationship is metabolically essential: the oocyte depends on cumulus cells for nutrients, signaling molecules, and developmental cues throughout its maturation. What Sasaki and Kawahara wanted to know was whether this dependency could become a liability during a viral attack.

To model the situation, the researchers used vesicular stomatitis virus, or VSV, a bullet-shaped RNA virus that is a standard laboratory tool for studying antiviral immunity. VSV enters cells through clathrin-dependent endocytosis and replicates rapidly in the cytoplasm, making it a reliable trigger of the innate immune pathways that cells use to detect RNA viruses. The team exposed mouse cumulus–oocyte complexes to the virus and then assessed how the cells responded at the level of gene expression, using quantitative real-time PCR to measure antiviral transcripts. In parallel, they tracked developmental outcomes by fertilizing the exposed oocytes in vitro and counting how many progressed through cleavage divisions and on to the blastocyst stage, the last step before implantation.

The gene expression analysis revealed a striking asymmetry between the two cell types in the complex. Ovulated oocytes did express retinoic acid-inducible gene-I, known as RIG-I, which is the cytosolic receptor that detects RNA viruses inside infected cells. But the oocytes lacked expression of two other key sensors of the RIG-I family: melanoma differentiation-associated gene 5, or MDA5, and laboratory of genetics and physiology 2, or LGP2. These helicase genes were present in the cumulus cells. The finding matters because the RIG-I family of DExD/H-box helicases forms the front line of intracellular RNA virus detection, with RIG-I and MDA5 recognizing different classes of viral RNA and LGP2 acting as a regulatory partner that fine-tunes their activity. The differential expression suggests that the oocyte’s antiviral surveillance toolkit is incomplete, and that its defenses may rely heavily on the completeness of the cumulus cells’ immune machinery.

When intact cumulus–oocyte complexes were exposed to VSV, the consequences for development were clear. The virus significantly impaired preimplantation development, reducing both the rate at which fertilized eggs underwent cleavage and the rate at which embryos formed blastocysts. Yet when the researchers looked for evidence of actual viral infection inside the oocytes and early embryos, they found none. The authors attribute this protection to the zona pellucida, the glycoprotein shell that surrounds the oocyte and early embryo and acts as a physical barrier. This result reframes the problem: the damage to development occurs without the virus ever setting foot inside the cell it ultimately harms.

Several follow-up experiments cemented the indirect mechanism. First, when the researchers stripped the cumulus cells away and exposed denuded oocytes directly to VSV, the oocytes neither induced antiviral gene expression nor showed developmental defects. On their own, the eggs simply did not respond to the virus. Second, and most tellingly, when uninfected oocytes were co-cultured with VSV-infected cumulus cells, their development was impaired—demonstrating that the mere presence of infected neighbors, with no virus reaching the oocyte, was sufficient to cause the damage. The virus, in effect, converted the egg’s own nurse cells into a source of developmental toxicity.

The molecular signature of the infected cumulus cells explained why. The infected cells exhibited a robust antiviral response, with significant upregulation of RIG-I itself, interferon-beta, interleukin-6, and tumor necrosis factor-alpha. Interferon-beta is the classic first-responder signal of the antiviral state, while interleukin-6 and tumor necrosis factor-alpha are inflammatory cytokines that can act on neighboring cells. Crucially, the researchers found that oocytes and zygotes express the receptor subunits for interleukin-6, encoded by the genes Il6ra and Gp130. This means the egg is structurally equipped to receive and respond to IL-6 signals arriving from its surroundings. The interleukin-6 pathway is already known to play roles in preimplantation embryos, where the IL-6 family cytokine leukemia inhibitory factor is essential for implantation, and the IL-6/STAT3 axis has been linked to anti-apoptotic signaling in mouse embryos. The new data identify IL-6 as a candidate mediator of the developmental impairment caused by infected cumulus cells.

The study’s authors frame the findings as revealing both the protective and the vulnerable nature of the cumulus–oocyte complex during viral challenge. The cumulus cells act as a shield: their complete antiviral sensor repertoire allows them to detect and respond to the virus, and the physical barrier of the zona pellucida keeps the virus out of the oocyte. But the same activation that defends the complex also floods the perivitelline environment with inflammatory cytokines, and the oocyte, which lacks its own full complement of viral sensors, appears susceptible to the paracrine consequences. The work thus provides a mechanistic account of how the maternal inflammatory microenvironment can influence early embryonic success, even in the absence of direct infection of the embryo itself.

The implications extend to a broader literature on viral infection and fertility. Hepatitis E virus has been shown to replicate in the ovary and promote oocyte apoptosis in rabbits, and Zika virus has been shown to cause acute infection and inflammation in the mouse ovary, with sexual transmission routes documented in mouse models. Herpes simplex virus type 2 sheds asymptomatically in the human female genital tract, and viral infection of the ovaries has been shown to compromise pregnancy while also revealing innate immune mechanisms that protect fertility. The new study adds a distinct mechanism to this list: not direct ovarian infection, and not viral tropism for the gamete, but the transformation of the egg’s own supporting cells into cytokine factories that compromise its developmental competence. This pathway could be relevant to unexplained fertility deficits associated with systemic or reproductive tract viral illness.

For the assisted reproduction field, the results suggest that the health of cumulus cells is not merely a marker of oocyte quality but an active determinant of embryo outcomes under immune challenge. The work was supported by JSPS KAKENHI grants 24K09199, awarded to Sasaki, and 24K01902, awarded to Kawahara, and all animal experiments were approved by the Regulatory Committee for the Care and Use of Animals of Hokkaido University. The authors note that the datasets supporting the developmental rate findings are available in the supplementary materials, with other data available from the corresponding author on reasonable request. Future work, the study implies, will need to test whether blocking interleukin-6 signaling during viral illness can rescue the developmental potential of exposed oocytes, and whether the same paracrine mechanism operates in other species, including humans—questions that could shape how fertility preservation is approached in patients confronting acute viral infections of the reproductive tract.

Subject of Research: Antiviral responses of mouse cumulus–oocyte complexes and indirect viral impairment of oocyte developmental competence via cumulus cell inflammatory signaling.

Article Title: Viral Infection of Cumulus Cells Impairs the Developmental Competence of Ovulated Mouse Oocytes

Article References: Sasaki, K., & Kawahara, M. (2026). Viral Infection of Cumulus Cells Impairs the Developmental Competence of Ovulated Mouse Oocytes. Biochemical Genetics. https://doi.org/10.1007/s10528-026-11449-4

Image Credits: AI Generated

DOI: 10.1007/s10528-026-11449-4

Keywords: oocyte, cumulus cells, vesicular stomatitis virus, antiviral response, RIG-I, interleukin-6, zona pellucida, fertility, preimplantation embryo, paracrine signaling, viral infection, reproductive immunology

The research, published in The Journal of Antibiotics, focused on CSA-13, the prototype of a family of laboratory-designed molecules called ceragenins. Unlike antimicrobial peptides, which are short chains of amino acids that the innate immune system deploys against invading pathogens, ceragenins are small sterol-based compounds built to reproduce the membrane-disrupting activity of those peptides without the fragility that limits their clinical use. Natural peptides are easily degraded by proteases and can be inactivated by DNA and actin released from dying tissue, conditions abundant in infected lungs. Ceragenins were engineered to sidestep those weaknesses while retaining a positively charged surface that binds to and permeabilizes bacterial membranes, and to additionally modulate inflammatory signaling through pathways involving innate immune receptors.

To test whether CSA-13 could protect the kidneys during pneumonia-induced sepsis, the team, led by Ugur Aksu of Istanbul University together with colleagues at several Turkish institutions and Paul B. Savage of Brigham Young University, worked with female C57/BL6 mice randomly assigned to four experimental groups of six animals each. One group served as a healthy control, while a second was subjected to Pseudomonas pneumonia-induced sepsis and left untreated. The remaining two groups received sepsis induction followed by either a low or a high dose of CSA-13 delivered intraperitoneally, a route that allowed the compound to circulate systemically after the infection had taken hold. The design deliberately modeled a treatment scenario rather than prophylaxis, asking whether the ceragenin could intervene after septic injury had already begun.

The investigators then tracked three interlocking dimensions of sepsis-related renal damage. Renal injury was quantified using plasma cystatin C, a small protein widely regarded as a more sensitive and reliable marker of glomerular filtration than traditional creatinine measurements because it is produced at a constant rate and is not confounded by muscle mass in the same way. Inflammation was assessed by measuring interleukin-6 concentrations in kidney tissue, since IL-6 is a central cytokine amplifier of the septic response and elevated tissue levels correlate with worse outcomes in acute kidney injury. Finally, glycocalyx integrity was evaluated through plasma hyaluronan, a glycosaminoglycan that is shed into the bloodstream when the endothelial glycocalyx—a delicate gel-like layer coating the interior surface of blood vessels—is degraded during systemic inflammation.

The glycocalyx deserves particular attention because it has emerged in recent years as both a diagnostic window and a therapeutic target in sepsis. This carbohydrate-rich coating on endothelial cells acts as a barrier that regulates vascular permeability, limits inappropriate adhesion of leukocytes, and maintains the selective sieving properties of the glomerular filtration barrier in the kidney. During sepsis, enzymes and inflammatory mediators shred the glycocalyx, releasing fragments such as hyaluronan into the circulation and simultaneously leaving the vasculature leaky and prothrombotic. In the kidney, this shedding contributes to the breakdown of filtration barriers that defines acute kidney injury. A therapy that preserves or restores the glycocalyx could therefore interrupt a critical step in the cascade from infection to organ failure, which is precisely what the researchers hoped CSA-13 might achieve.

The results were striking in two of the three domains. Both the low and high doses of CSA-13 successfully restored plasma cystatin C toward normal levels, indicating that kidney function was substantially preserved despite the septic insult. Equally important, tissue levels of interleukin-6, which surged in untreated septic mice, fell back to values indistinguishable from those of healthy controls in animals receiving either dose of the ceragenin. This dual effect—preserving filtration capacity while suppressing a key inflammatory cytokine within the kidney itself—suggests that CSA-13 acts not merely as an antibiotic reducing bacterial load but also as an immunomodulatory agent dampening the local renal inflammatory response that drives tissue damage.

Histological examination reinforced the biochemical findings. Under the microscope, the kidneys of untreated septic mice displayed the expected hallmarks of acute injury, including disruption of cellular architecture and tissue disorganization. In contrast, mice treated with either dose of CSA-13 largely maintained cellular integrity, with renal tissue structure closely resembling that of the healthy control group. The consistency of the protection across both low and high dosing regimens is noteworthy from a translational standpoint, because it hints that effective renoprotection does not require aggressive dosing, a potentially valuable property given that dose-dependent toxicity is a persistent concern with many antimicrobial agents used in critically ill patients.

The one measure that resisted the treatment was glycocalyx degradation. Plasma hyaluronan, the surrogate marker of glycocalyx shedding, remained elevated in septic mice whether or not they received CSA-13, at either dose. The authors’ conclusion was measured: the administration of the ceragenin did not substantially alter hyaluronan levels in infected animals. This finding matters because it delineates the boundary of the compound’s protective reach. CSA-13 appears to safeguard kidney function and cellular structure primarily through antimicrobial and anti-inflammatory mechanisms rather than by directly preserving the endothelial glycocalyx. In practical terms, other therapeutic strategies may still be needed alongside ceragenin therapy to address the vascular barrier failure that accompanies sepsis, and future studies will need to determine whether the persistent hyaluronan elevation reflects ongoing glycocalyx damage that is functionally compensated by other protective effects.

Even with that limitation, the study carries significant implications at a moment when antimicrobial resistance is eroding the effectiveness of the clinical arsenal against Pseudomonas aeruginosa, a notoriously drug-resistant Gram-negative pathogen and a leading cause of hospital-acquired and ventilator-associated pneumonia. Previous work has demonstrated that ceragenins retain activity against multidrug-resistant clinical isolates, function in challenging biological environments such as cystic fibrosis sputum, and show promise in animal models of peritoneal, urinary tract, and intestinal infection, as well as in early clinical studies of ceragenin-coated endotracheal tubes designed to prevent ventilator-associated pneumonia. The present findings extend this evidence base by demonstrating systemic renoprotective and anti-inflammatory effects in the septic context, raising the possibility that ceragenins could one day serve as combination agents that simultaneously control infection and prevent downstream organ damage.

The researchers conclude that intraperitoneal CSA-13 administration decreases renal interleukin-6 levels and protects both kidney function and cellular integrity in pneumonia-induced sepsis, positioning the compound as a candidate component of treatment protocols aimed at preventing acute kidney injury in this setting. Much work remains before such a protocol could reach patients: the current study involved small groups of animals, a single time course, and a single sepsis model, and questions of optimal dosing, timing, safety, and efficacy relative to standard antibiotics are unresolved. Moreover, the authors acknowledge funding support from N8 Medical, Inc., a company with commercial interest in ceragenin technology, and one coauthor serves as a paid consultant, considerations that will warrant scrutiny as the work moves toward independent replication. Nevertheless, the convergence of preserved filtration markers, normalized inflammatory cytokines, and protected tissue architecture paints a coherent and encouraging picture. If subsequent studies confirm these results, ceragenins may carve out a distinctive niche in critical care medicine—molecules conceived as peptide mimics but proving their worth as protectors of the organs that sepsis strikes hardest.

The choice of cystatin C as the primary renal endpoint reflects a broader shift in nephrology toward biomarkers that detect injury earlier than creatinine. Because cystatin C is freely filtered and reabsorbed by proximal tubular cells, rising plasma concentrations can signal declining filtration before conventional tests change, making it particularly valuable in dynamic conditions such as sepsis where hours matter for intervention.

Interleukin-6 likewise carries clinical weight beyond the laboratory. Circulating IL-6 has been associated with progression to severe sepsis and mortality in critically ill patients, and the cytokine drives endothelial activation, capillary leak, and recruitment of inflammatory cells into renal tissue. The observation that kidney tissue IL-6 normalized with treatment, rather than merely declining, suggests the compound interrupted the local amplification loop rather than blunting it partially.

The persistence of elevated hyaluronan despite preserved kidney structure also raises mechanistic questions. Glycocalyx shedding is mediated by enzymes such as heparanase and hyaluronidase activated during inflammation, and their activity may outlast the cytokine surge. Alternatively, hyaluronan released from injured pulmonary tissue could contribute to circulating levels independently of renal vascular damage, a possibility that would reconcile normal histology with unchanged biomarker values.

For Pseudomonas aeruginosa specifically, the findings arrive as the pathogen appears on global watchlists of critical-priority drug-resistant bacteria. Compounds with dual antimicrobial and immunomodulatory activity could reduce reliance on high-dose beta-lactams and aminoglycosides, agents whose nephrotoxicity compounds septic renal injury. Whether ceragenins can deliver that benefit in humans will depend on pharmacokinetic studies and larger, independent animal work before clinical trials become realistic.

Subject of Research: Evaluation of the ceragenin CSA-13 for renoprotection, anti-inflammatory effects, and glycocalyx preservation in a murine model of Pseudomonas pneumonia-induced sepsis.

Article Title: CSA-13 treatment in a murine model of Pseudomonas pneumonia-induced sepsis and its effects on renal injury, inflammation, and glycocalyx derangement

Article References: Aksu, U., Bozkurt-Guzel, C., Erkose-Genc, G., Tok, O. E., Esrefoglu, M., Oyardi, O., & Savage, P. B. (2026). CSA-13 treatment in a murine model of Pseudomonas pneumonia-induced sepsis and its effects on renal injury, inflammation, and glycocalyx derangement. The Journal of Antibiotics. https://doi.org/10.1038/s41429-026-00957-5

Image Credits: AI Generated

DOI: 10.1038/s41429-026-00957-5

Keywords: ceragenin, CSA-13, sepsis, acute kidney injury, Pseudomonas aeruginosa, pneumonia, interleukin-6, cystatin C, glycocalyx, hyaluronan, antimicrobial peptides, renal inflammation

Major depressive disorder is far more than a mood condition. Beyond low mood and lost interest, many patients struggle with memory, attention, and executive function—deficits that often persist between depressive episodes and interfere with work, relationships, and daily life. At the same time, researchers have long noted that depression travels with metabolic disturbances such as insulin resistance, and with elevated levels of inflammatory molecules circulating in the blood. What has remained murky is how these threads connect to one another, and why some patients develop cognitive problems while others do not.

The research team, led by investigators at Xiamen Xianyue Hospital affiliated with Xiamen Medical College, recruited 300 people with major depressive disorder—100 men, 100 premenopausal women, and 100 postmenopausal women—along with 150 age- and body mass index-matched healthy controls. Participants were assessed between February 2021 and September 2024 using a battery of measures designed to capture the full biological and clinical picture: the triglyceride-glucose index, a simple calculated marker of insulin resistance; serum neuropeptide Y measured by enzyme-linked immunosorbent assay; inflammatory markers including interleukin-6, tumor necrosis factor-alpha, and C-reactive protein; appetite ratings on a visual analog scale; depression severity on the 17-item Hamilton Depression Rating Scale; and cognition using the Montreal Cognitive Assessment.

The results were striking from the first comparison. Patients with depression showed significantly higher triglyceride-glucose index values, higher neuropeptide Y levels, and greater inflammation than controls, alongside markedly lower cognitive scores. Neuropeptide Y, a peptide released during stress that also regulates appetite and energy balance, was elevated most prominently in premenopausal women—a detail that immediately signaled the importance of sex and reproductive status in the underlying biology.

Correlation analyses deepened the picture. Neuropeptide Y tracked positively with both the triglyceride-glucose index and appetite ratings, with correlation coefficients ranging from 0.43 to 0.52, suggesting that as metabolic dysfunction worsened, the peptide rose in tandem with increased appetite. But the same molecule told a darker story about the brain: it correlated negatively with cognitive performance, with coefficients between −0.35 and −0.46. The stronger a patient’s metabolic derangement and appetite disturbance, the worse their performance on tests of memory and thinking—and once again, these relationships were strongest in premenopausal women.

To test whether neuropeptide Y actually serves as a conduit between metabolism and cognition, the team used a statistical technique called moderated mediation analysis. The findings revealed a layered pathway. Inflammation partially mediated the link between neuropeptide Y and cognitive scores, accounting for roughly 39 percent of the total effect. In other words, high neuropeptide Y appears to fuel inflammatory processes, and those inflammatory signals in turn chip away at cognitive function.

The full chain ran even further back. Neuropeptide Y and inflammation jointly mediated the relationship between the triglyceride-glucose index and cognition, with the joint indirect effect explaining 36.88 percent of the total association. Critically, this mediation was moderated by sex and reproductive status: the pathway was most powerful in premenopausal women, where the indirect effect accounted for 42.37 percent of the total—meaning that in younger women, nearly half of the connection between poor metabolic health and cognitive impairment flows through elevated neuropeptide Y and inflammation.

The authors suggest several mechanisms that could underlie these sex differences. Neuropeptide Y levels are known to vary with estrogen status, and estrogen interacts with both metabolic regulation and immune signaling. Premenopausal women, with higher circulating estrogen, may mount a distinct metabolic and inflammatory response to depression—one in which appetite changes driven by neuropeptide Y are more pronounced, and in which the downstream inflammatory consequences for the brain are amplified. After menopause, this coupling appears to loosen, producing a different risk architecture.

Beyond clarifying mechanism, the study carries immediate clinical promise in the form of a diagnostic tool. The researchers combined four blood measures—the triglyceride-glucose index, neuropeptide Y, interleukin-6, and tumor necrosis factor-alpha—into an integrated biomarker panel and tested its ability to distinguish patients with cognitive impairment using receiver operating characteristic analysis. The panel achieved an area under the curve of 0.869, substantially outperforming the triglyceride-glucose index alone, which managed 0.748. The difference was statistically robust. A simple blood draw, in other words, could one day flag which patients with depression are most at risk of the cognitive dimension of the illness.

The authors caution that the cross-sectional design captures only a snapshot, so cause and effect cannot be definitively established, and longitudinal studies are warranted to confirm whether correcting metabolic dysfunction early can prevent cognitive decline. Still, the implications are considerable. If the pathway holds, interventions targeting insulin sensitivity, neuropeptide Y signaling, or inflammation—tailored to a patient’s sex and reproductive stage—could offer a biological handle on the cognitive symptoms that make depression so disabling. The study is also a reminder that psychiatric illness is embodied: mood, metabolism, immunity, and hormones are not separate stories but a single, sex-specific web, and untangling it may finally explain why the brain falters when the body’s chemistry goes awry.

Neuropeptide Y itself has a long research history that helps explain why it sits at the center of this pathway. It is one of the most abundant neuropeptides in the mammalian nervous system, co-released with norepinephrine during stress, where it classically acts to buffer the cardiovascular and emotional impact of acute stressors. Yet the same peptide is also a potent orexigenic signal, stimulating food intake and promoting fat storage when released in hypothalamic circuits. This dual identity—stress resilience on one hand, metabolic promotion on the other—may account for the seemingly paradoxical findings in the new study, in which higher neuropeptide Y accompanied greater appetite but poorer cognition. Chronic elevation of a peptide designed for short-term stress responses may carry costs that only become apparent over time, particularly in metabolic and immune systems.

The choice of the triglyceride-glucose index as the study’s metabolic anchor reflects broader trends in cardiometabolic research. Unlike direct measures of insulin resistance, which require fasting insulin assays or dynamic testing, the index is computed from routine fasting triglyceride and glucose values, making it inexpensive and easy to deploy in large cohorts and clinical settings. It has been validated across numerous populations as a surrogate for insulin resistance and has repeatedly been associated with adverse outcomes ranging from cardiovascular disease to non-alcoholic fatty liver disease. Its appearance here as a predictor of cognitive impairment in depression extends that literature into psychiatry, and its practicality matters: a marker that requires only a standard metabolic panel could be incorporated into routine psychiatric care far more readily than specialized testing.

The inflammatory markers used in the study likewise represent well-characterized players in the biology of depression. Interleukin-6 and tumor necrosis factor-alpha are pro-inflammatory cytokines that can signal to the brain through both humoral and neural routes, influencing neurotransmitter metabolism, hypothalamic-pituitary-adrenal axis activity, and neuroplasticity. Elevated peripheral inflammation has been reported in subsets of depressed patients for decades, and previous work has linked inflammatory activity to specific symptom dimensions, including fatigue, psychomotor slowing, and cognitive difficulties. The present findings sit comfortably within that tradition while adding a mechanistic twist: inflammation appears not simply as a correlate of depression but as a downstream conduit through which metabolic and neuropeptide signals reach the brain.

The statistical architecture of the study also deserves note. Moderated mediation analysis allows researchers to test both an indirect pathway—whether one variable transmits the effect of another—and whether that transmission differs across subgroups. By applying this framework separately to men, premenopausal women, and postmenopausal women, the investigators could quantify how the same biological chain varies in strength depending on hormonal context. The confidence intervals reported for the indirect effects excluded zero across the full sample and in the premenopausal subgroup, lending statistical weight to conclusions that might otherwise rest on visual inspection of subgroup differences alone.

The diagnostic analysis likewise illustrates methodological principles worth understanding. The area under the receiver operating characteristic curve expresses, on a scale from 0.5 to 1.0, how well a marker separates affected from unaffected individuals, with values above 0.8 generally considered useful discrimination. The jump from 0.748 for the triglyceride-glucose index alone to 0.869 for the four-marker panel, confirmed by a formal comparison test, demonstrates the additive value of measuring multiple biological dimensions rather than any single one. This multibiomarker approach mirrors strategies already standard in cardiovascular risk assessment, where combinations of lipid, inflammatory, and metabolic measures outperform any lone indicator.

Finally, the study’s framing around reproductive stage rather than sex alone points toward a more nuanced future for psychiatric biomarker research. Menopause represents a natural experiment in estrogen withdrawal, and the loosening of the neuropeptide Y–inflammation–cognition coupling observed after menopause suggests that ovarian hormones actively shape how metabolic stress is translated into neural injury. Disentangling these hormonal contributions may ultimately identify which patients benefit most from metabolic or anti-inflammatory interventions, moving psychiatry closer to biologically stratified treatment.

Subject of Research: How neuropeptide Y connects metabolic dysfunction and inflammation to cognitive impairment in major depressive disorder across sex and menopausal status.

Article Title: Interplay of neuropeptide Y, metabolic dysfunction, and inflammation in cognitive impairment of major depressive disorder: a sex-stratified study

Article References: Yuan, Q., Elhassan, M. A. M., Zhang, H., Wang, L., Zhu, X., Wu, Z., Lin, D., & Huang, Z. (2026). Interplay of neuropeptide Y, metabolic dysfunction, and inflammation in cognitive impairment of major depressive disorder: a sex-stratified study. Biology of Sex Differences. https://doi.org/10.1186/s13293-026-00981-y

Image Credits: AI Generated

DOI: 10.1186/s13293-026-00981-y

Keywords: major depressive disorder, neuropeptide Y, cognitive impairment, triglyceride-glucose index, inflammation, insulin resistance, sex differences, menopause, biomarkers, interleukin-6, IL-6, MoCA